SBRI19005U Pharma I - Drug Discovery and Preclinical Development
BRIDGE - Translational Excellence Programme
This course gives an overview of the pre-clinical phase of discovery and development of medical drugs. The participants will be able to communicate professionally with the various specialist groups within the area of drug development.
The topics taught are:
- Target finding and translational validation
- Small-molecule hit identification and lead optimization
- Peptides and proteins as drugs
- Non-clinical safety
Upon completing the course, participants should be able to:
Knowledge
- Give an overview of the pre-clinical phase of discovery and development of medicines.
- Identify correct professional terms in drug discovery and pre-clinical development of medicines.
- List major steps and elements of the pre-clinical drug development process.
- Outline definitions of key concepts and the fundamentals of the major disciplines in drug discovery and pre-clinical development.
Skills
- Appraise the integration of the various basic disciplines into the process of discovery and pre-clinical development of medicines.
- Analyse the sequence and flow of the various steps in the process of drug discovery and pre-clinical development.
Competences
- Liaise with all steps of drug discovery and pre-clinical development.
- Identify critical factors and bottlenecks that influence the pre-clinical drug development process.
- Promote and state milestones for the progress of the pre-clinical development of a medical product.
- Communicate professionally with the various specialist groups within the area of development of medicines.
Course literature will be published on Absalon.
The first five course days of the Pharma I course corresponds to week 1 of a course in the Professional Master’s Programmes "Master of Industrial Drug Development" (MIND), and the "Master of Medicines Regulatory Affairs" (MRA). The MIND, MRA, and BRIDGE participants are taught together during this week. The 6th course day is only for BRIDGE participants. For the BRIDGE participants, the course includes group project work where the participants will study and describe the discovery of a known drug in an oral presentation in plenum.
The course will end with an evaluation where participants must reflect on course learning outcomes and give feedback for course development.
- Category
- Hours
- Lectures
- 22
- Preparation
- 20
- Project work
- 8
- Total
- 50
The BRIDGE – Translational Excellence Programme offers a few selected graduated PhDs a two-year postdoctoral fellowship in translational medicine. This course is only available to the fellows enrolled in the programme. Fellows are automatically enrolled in this course upon admission to the programme.
For further information about the programme, please go to the website: www.bridge.ku.dk
- Credit
- 0 ECTS
- Type of assessment
- Continuous assessmentRequirement to attend classes
- Type of assessment details
- Attendance and active participation, including the project work and participant presentation the last course day.
- Exam registration requirements
Participants are automatically registered for the examination upon admission to the BRIDGE - Translational Excellence Programme.
- Aid
- All aids allowed
- Marking scale
- passed/not passed
- Censorship form
- No external censorship
Criteria for exam assesment
Active contribution and course participation according to the BRIDGE Guidelines and Practicalities.
Course information
- Language
- English
- Course code
- SBRI19005U
- Credit
- 0 ECTS
- Level
- Part Time MasterPh.D.
- Placement
- Spring
- Schedule
- See course dates and course programme in Absalon.
- Course capacity
- 15 participants
Study board
- Study Board for the Professionel Master´s Degree Programmes at The Faculty og Health and Medical Science
Contracting department
- Department of Drug Design and Pharmacology
Contracting faculty
- Faculty of Health and Medical Sciences
Course Coordinators
- Anders Bach (anders.bach@sund.ku.dk)